在西班牙裔患有转移性结肠直肠癌的西班牙裔患者中,生物药物的有效性
Riya Patel1, Abdissa Negassa2, Seda S Tolu3
1Department of Medical Oncology, The State University of New York, University at Buffalo, Buffalo, NY; Department of Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Clinical colorectal cancer
|November 2, 2023
概括
生物化疗,结合化疗和生物药物,显著改善了转移性结直肠癌 (mCRC) 的西班牙裔患者的生存率. 这种现实世界的证据表明,它的好处跨越了所有种族和民族群体.
科学领域:
- 在瘤学瘤学.
- 相对有效性研究研究比较
- 健康差异 在健康上的差异
背景情况:
- 随机试验显示生物药物与转移性结直肠癌 (mCRC) 化疗的生存益处.
- 西班牙裔人口的代表性不足,导致这一人口群体的结果定义不佳.
- 这项研究调查了西班牙裔mCRC患者的现实世界生物药物益处.
研究的目的:
- 确定生物药在mCRC中的生存优势是否延伸到西班牙裔患者.
- 利用比较有效性研究方法来分析现实世界的数据.
- 为不同患者群体的治疗决策提供信息.
主要方法:
- 使用SEER-Medicare链接数据库和医院数据 (2001-2016) 的回顾性队列研究.
- 确定了182名西班牙裔mCRC患者,将他们分为化疗或生物化疗组.
- 治疗权重的逆概率 (IPTW) 和考克斯回归分析了整体存活率 (OS).
主要成果:
- 化学疗法的中位数是11.3个月,而生物化学疗法的中位数是17.0个月.
- 生物化疗显示,危险率降低了39% (p=.0236).
- 在这项研究中,72%的西班牙裔患者接受了生物药物治疗.
结论:
- 生物化疗与mCRC的西班牙裔患者的寿命延长有关.
- 这些发现支持向所有mCRC患者提供生物化疗,以最大限度地提高临床效益.
- 现实世界的数据证实了生物制剂在代表性不足的少数群体中的有效性.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
146
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
146
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
147
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
147
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134


